Research biologists and clinicians can use this new platform to analyse OMICS data.
Insilico Medicine, a partner company of Hong Kong Science and Technology Parks Corporation (HKSTP), has rolled out Pandomics – an AI-powered platform to empower pharmaceutical target and drug discovery pipeline, the company said in a press release. The platform will reportedly aid research biologists and clinicians to perform OMICS data analytics and interpretation, even if they have no prior knowledge of computational biology or bioinformatics.
Insilico Medicine started working on an engine for target identification back in 2014. Since then, the technology has been validated through several successful partnering initiatives with pharmaceutical companies and research organisations as well as through its own internal drug development programs, according to HKSTP.
Pandomics aims to be the go-to platform for all biologists and clinicians, working with various OMICS datasets, and to quickly analyse, interpret and visualise data effectively in order to classify patient cohorts more accurately, Insilico Medicine added.
Do you know more about this story? Contact us anonymously through this link.